Polar Capital Holdings Plc Has $1.49 Million Position in Stryker Co. (NYSE:SYK)

Polar Capital Holdings Plc lowered its holdings in Stryker Co. (NYSE:SYK - Free Report) by 53.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,128 shares of the medical technology company's stock after selling 4,730 shares during the period. Polar Capital Holdings Plc's holdings in Stryker were worth $1,486,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of SYK. Norges Bank acquired a new stake in shares of Stryker in the fourth quarter valued at approximately $1,710,744,000. Raymond James Financial Inc. acquired a new position in shares of Stryker during the fourth quarter valued at approximately $353,394,000. FMR LLC increased its stake in shares of Stryker by 10.0% during the fourth quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock valued at $2,892,946,000 after acquiring an additional 727,850 shares during the period. Proficio Capital Partners LLC increased its stake in shares of Stryker by 52,520.8% during the fourth quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company's stock valued at $214,660,000 after acquiring an additional 595,061 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Stryker by 13.2% during the fourth quarter. Northern Trust Corp now owns 3,606,237 shares of the medical technology company's stock valued at $1,298,426,000 after acquiring an additional 420,153 shares during the period. Institutional investors own 77.09% of the company's stock.

Stryker Stock Down 1.4%

Shares of SYK stock traded down $5.39 on Tuesday, hitting $389.30. The company's stock had a trading volume of 1,047,447 shares, compared to its average volume of 1,346,784. The firm's fifty day moving average price is $367.24 and its 200-day moving average price is $375.80. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The stock has a market capitalization of $148.59 billion, a price-to-earnings ratio of 50.17, a P/E/G ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. The company had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The company's quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the firm posted $2.50 earnings per share. Research analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. Stryker's payout ratio is 45.41%.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the transaction, the director now owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 5.90% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SYK. Wells Fargo & Company raised their price objective on shares of Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. Citigroup restated a "buy" rating and issued a $450.00 price target on shares of Stryker in a research report on Wednesday, February 26th. BTIG Research set a $403.00 price target on shares of Stryker and gave the stock a "buy" rating in a research report on Monday, April 14th. StockNews.com lowered shares of Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, March 6th. Finally, Roth Mkm lifted their price target on shares of Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $427.05.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.